

22257 – Response Letter

Regarding Manuscript Number 22257, title, “Should Multi-Gene Panel Testing Replace Limited BRCA1/2 Testing?: A Review of Genetic Testing for Hereditary Breast and Ovarian Cancers”

Reviewer One: The question posed is “what is the definition of a patient.” It is a great point since some would argue that anyone can or should undergo gene testing. For the purposes of this manuscript, we have clarified our definition as those at risk for hereditary breast or ovarian cancer and have highlighted this point as well.

Reviewer Two: The reviewer has suggested that this manuscript is “somewhat biased towards a positive view of genetic panels” and that in this reviewer’s opinion it “overplays the success of panels and underplays issues pertaining to unverified findings.” To be accurate, the section on “Limitations and Concerns” of panel testing is actually 31% *longer* than the section on “Benefits” of panel testing, since, indeed, we agree there are many potential issues with panel testing. In addition, however, we have included reference to the recent 2015 Easton, et al. New England of Journal Medicine paper published in this area, and have provided even further balance on this topic.